Chase Doyle

Authored Items
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA 2017 Highlights
Prescription Drug Use High Among Survivors of Childhood Cancers
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Survivorship
Shared Antigens Yield Promising Targets for Cancer Prevention
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Immunotherapy
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA 2017 Highlights
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA 2017 Highlights
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA 2017 Highlights
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA 2017 Highlights
Chemotherapy Treatment Considerations in Special Patient Populations
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA 2017 Highlights
Rapid Adoption of Novel Oncology Drugs Improves Overall Survival
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Survivorship
Incorporating Genetics into Clinical Care
Chase Doyle
TON - July 2017, Vol 10, No 4 in Survivorship
Prescription Drug Use High Among Survivors of Childhood Cancers
Chase Doyle
TON - May 2017, Vol 10, No 3 in Survivorship
Shared Antigens Yield Promising Targets for Cancer Prevention
Chase Doyle
TON - May 2017, Vol 10, No 3 in Immunotherapy
Mechanisms of Response and Resistance to Immunotherapy
Chase Doyle
TON - May 2017, Vol 10, No 3 in Immunotherapy
Right-to-Try Laws Challenge Pharmacy Code of Ethics
Chase Doyle
TOP - May 2017, Vol 10, No 2 in HOPA 2017 Highlights
Provider Status Initiative Takes Center Stage at HOPA
Chase Doyle
TOP - May 2017, Vol 10, No 2 in HOPA 2017 Highlights
Nivolumab versus Cabozantinib: Second-Line Therapy for Metastatic Renal-Cell Carcinoma Still Unresolved
Chase Doyle
TOP - May 2017, Vol 10, No 2 in HOPA 2017 Highlights
Plinabulin Improves Survival in Non–Small-Cell Lung Cancer
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Lung Cancer
Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Lung Cancer
Mechanisms of Response and Resistance to Immunotherapy
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Immunotherapy
Mutational Load and T-Cell–Inflamed Microenvironment May Predict Response to Pembrolizumab
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Immunotherapy
Reducing Disparities in Survivorship Care
Chase Doyle
TON - March 2017, Vol 10, No 2 in Survivorship
Adolescent and Young Adult Survivorship: What We Still Need to Understand
Chase Doyle
TON - March 2017, Vol 10, No 2 in Survivorship
E-Learning Series Improves Provider Knowledge of Cancer Survivorship
Chase Doyle
TON - March 2017, Vol 10, No 2 in Survivorship
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
In the News: Oncology - February 2017 in Conference Correspondent
Drug–Drug Interactions Linked to Inferior Survival in Older Patients with Aggressive Lymphoma
Chase Doyle
TOP - February 2017, Vol 10, No 1 in Palliative Care
Advanced Practitioners Add Value to a Hematology/Oncology Practice
Chase Doyle
TON - January 2017, Vol 10, No 1 in Conference Correspondent
Targeted Team Approach Improves Engagement of Advance Care Planning
Chase Doyle
TON - January 2017, Vol 10, No 1 in Palliative Care
Edmonton Symptom Assessment Scale Has Minimal Impact on Clinical Time
Chase Doyle
TON - January 2017, Vol 10, No 1 in Supportive Care
Palliative Care for Caregivers: Implementing Caregiver Support Programs
Chase Doyle
TON - November 2016, Vol 9, No 6 in Palliative Care
Managing Immune-Related Toxicities
Chase Doyle
TON - November 2016, Vol 9, No 6 in Supportive Care
Managing Immune-Related Toxicities
Chase Doyle
TOP - November 2016, Vol 9, No 4 in Supportive Care
Improving Communication with Cancer Survivors: 4 Pivotal Conversations
Chase Doyle
TON May 2016 Vol 9 No 3 in Survivorship
Decision Aids: Facilitating Communication with Cancer Survivors
Chase Doyle
TON May 2016 Vol 9 No 3 in Survivorship
Survivorship Care: A Patient Advocate’s Prescription
Chase Doyle
TOP - May 2016, Vol 9, No 2 in Survivorship
Decision Aids: Facilitating Communication with Cancer Survivors
Chase Doyle
TOP - May 2016, Vol 9, No 2 in Survivorship
A New Paradigm for Survivorship Care: Assessing the Patient’s Priorities
Chase Doyle
TOP - May 2016, Vol 9, No 2 in Survivorship
Preparation of Nurses for Cancer Survivorship Care
Chase Doyle
TON March 2016 Vol 9 No 2 in Survivorship
Providing Oncology Care Across the Cancer Care Continuum
Chase Doyle
TON March 2016 Vol 9 No 2 in Survivorship
Bridging the Gap Between Pediatric and Adult Care
Chase Doyle
TON March 2016 Vol 9 No 2 in Survivorship
Immunotherapy Will Alter the NSCLC Treatment Landscape
Chase Doyle
TOP November 2015 Vol 8 No 4 in Immunotherapy
Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Chase Doyle
TOP November 2015 Vol 8 No 4 in Genitourinary Cancers
The Next Generation of Agents for Lung Cancer
Chase Doyle
TON November 2015 Vol 8 No 6 in Lung Cancer
Looking into the Future of Lung Cancer Research
Chase Doyle
TON November 2015 Vol 8 No 6 in Lung Cancer
Immunotherapy Will Alter the NSCLC Treatment Landscape
Chase Doyle
TON November 2015 Vol 8 No 6 in Lung Cancer
The Affordable Care Act: Extending Coverage to Millions of Americans
Chase Doyle
TON November 2015 Vol 8 No 6 in Healthcare Policy
FDA Drug Approvals: Earlier Availability for Promising Drugs
Chase Doyle
TON November 2015 Vol 8 No 6 in FDA News & Updates
Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Chase Doyle
Online First in Online First, Genitourinary Cancers
Stereotactic Body Radiation Therapy Shows Acceptable Urinary and Sexual Toxicity
Chase Doyle
TOP - August 2015, Vol 8, No 3 in Genitourinary Cancers
Higher Costs for Sunitinib versus Pazopanib in Patients with Renal-Cell Carcinoma
Chase Doyle
TOP - August 2015, Vol 8, No 3 in Genitourinary Cancers
Stereotactic Body Radiation Therapy Shows Acceptable Urinary and Sexual Toxicity
Chase Doyle
TON May 2015 Vol 8 No 3 in Genitourinary Cancers
Colorectal Cancer Survivors Frequently Report Bowel Dysfunction
Chase Doyle
TOP - May 2015, Vol 8, No 2 in Supportive Care
Biosimilar Effective for Chemotherapy-Induced Anemia in Patients with Colorectal Cancer
Chase Doyle
TOP - May 2015, Vol 8, No 2 in Best Practices
Investigational Drug for Cachexia Appears to Improve Survival
Chase Doyle
TOP - May 2015, Vol 8, No 2 in Colorectal Cancer
Investigational Drug for Cachexia Appears to Improve Survival Results
Chase Doyle
TON March 2015 Vol 8 No 2 in Colorectal Cancer
Colorectal Cancer Survivors Frequently Report Bowel Dysfunction
Chase Doyle
TON March 2015 Vol 8 No 2 in Supportive Care
Symptom Management Drives Value in Oncology
Chase Doyle
TOP - February 2015, Vol 8, No 1 in Supportive Care
Biosimilars: Ambiguity of FDA Terminology and Benefits of a Multidisciplinary Review Team
Chase Doyle
TOP - February 2015, Vol 8, No 1 in Best Practices
Addressing Patient Safety for Oral Chemotherapy
Chase Doyle
TOP - February 2015, Vol 8, No 1 in Best Practices
Palliative Care Sells Itself
Chase Doyle
TON - January 2015 Vol 8 No 1 in Palliative Care
Last modified: December 11, 2015